Atezolizumab for PD-L1-Selected Patients with NSCLC. Reply
N Engl J Med
.
2021 Feb 11;384(6):584-585.
doi: 10.1056/NEJMc2032432.
Authors
Roy S Herbst
1
,
Hiroshi Kuriki
2
,
David R Spigel
3
Affiliations
1
Yale School of Medicine, New Haven, CT roy.herbst@yale.edu.
2
Genentech, South San Francisco, CA.
3
Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN.
PMID:
33567202
DOI:
10.1056/NEJMc2032432
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Lung Neoplasms* / drug therapy
Substances
Antibodies, Monoclonal, Humanized
B7-H1 Antigen
atezolizumab